Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
about
Alpha-glucosidase inhibitors for type 2 diabetes mellitusThe amylase inhibitor montbretin A reveals a new glycosidase inhibition motifUpdate on the treatment of type 2 diabetes mellitusPharmacological inhibition of glucosylceramide synthase enhances insulin sensitivityCombination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbitsBinding mode analyses and pharmacophore model development for stilbene derivatives as a novel and competitive class of α-glucosidase inhibitorsNewer insights into the drug delivery approaches of α-glucosidase inhibitors.Iminosugars as therapeutic agents: recent advances and promising trends.Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.Comparative safety of newer oral antidiabetic drugs.Postprandial hyperglycaemia and vascular damage--the benefits of acarbose.Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemiaThe effect of electrostatic interactions on conformational equilibria of multiply substituted tetrahydropyran oxocarbenium ions.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Synthesis and α-glucosidase inhibitory mechanisms of bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a potential marine bromophenol α-glucosidase inhibitor.Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis.Postprandial effects of a polyphenolic grape extract (PGE) supplement on appetite and food intake: a randomised dose-comparison trial.In silico molecular docking and in vitro antidiabetic studies of dihydropyrimido[4,5-a]acridin-2-amines.Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping SyndromeSynthesis and glycosidase inhibitory activity of new hexa-substituted C8-glycomimetics.Thioglycoligase-based assembly of thiodisaccharides: screening as beta-galactosidase inhibitorsSynthesis of 5-azacastanospermine, a conformationally restricted azafagomine analogue.[Reducing postprandial glucose levels. Glucosidase antagonists].Computational mutagenesis reveals the role of active-site tyrosine in stabilising a boat conformation for the substrate: QM/MM molecular dynamics studies of wild-type and mutant xylanases.Novel pyridine-2,4,6-tricarbohydrazide thiourea compounds as small key organic molecules for the potential treatment of type-2 diabetes mellitus: In vitro studies against yeast α- and β-glucosidase and in silico molecular modeling.Pharmacokinetics, Tissue Distribution, and Elimination of Three Active Alkaloids in Rats after Oral Administration of the Effective Fraction of Alkaloids from Ramulus Mori, an Innovative Hypoglycemic Agent.Rapid identification of miglitol and its isomers by electrospray ionization tandem mass spectrometry.Organocatalyzed Novel Synthetic Methodology for Highly Functionalized Piperidines as Potent α-Glucosidase Inhibitors.Inhibition of α-glucosidase activity by N-deoxynojirimycin analogs in several insect phloem sap feeders.Molecular dynamics simulation integrating the inhibition kinetics of hydroxysafflor yellow A on α-glucosidase.Synthesis of furostanol glycosides: discovery of a potent α-glucosidase inhibitor.Evaluation of the anti-hyperglycemic effect and safety of microorganism 1-deoxynojirimycin.Development of liquid chromatographic method for the simultaneous determination of metformin and miglitol in human plasma: application to pharmacokinetic studiesA patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitolα-Carbonic anhydrases are sulfatases with cyclic diol monosulfate esters
P2860
Q24246908-1B620F9F-627C-4157-B9A7-A938CD2120D3Q27701657-50CE5592-17E1-42A7-AC00-D0F9CE8856A2Q28073342-FEEB4030-D498-4339-9CE9-3E5B09D9CBE2Q28287290-AFC5A2EA-6CE1-449E-87A6-E9B44C897FACQ28345454-5D59D68B-DECE-454E-ACC3-BCF0F0A45CE6Q28538918-578D2F85-0F0A-460C-82AB-C19381E4521AQ33453482-7D36F44D-9252-46ED-8A59-37C670BD862AQ34212463-37AACD0E-15C2-4FFE-AFF9-82946268A3CDQ34990233-B80A5019-1DC3-41CA-950C-DFADD3F0AADDQ36624990-248F0A86-EBB6-4FE4-B101-6E0CD9A5E345Q36632034-1067E988-2F9D-4E7A-A0F7-89311A424ABEQ36952365-400BD474-E13E-46F9-B5E2-5130BE10833DQ37171066-E5ECA8B0-02E6-4C72-9658-9E9F334EC872Q37509313-62436539-177E-43F5-A583-886680916BFCQ38086611-F315522B-379A-47CB-B049-938A56B9B40BQ38199526-A62F190B-5F44-40AA-B99C-935494201681Q38541323-4A4D3345-062F-4EFD-987E-06FDF3616302Q38563239-6D086508-513D-4449-9D6A-1EF0DD168166Q38669170-F40E3DDB-B50C-45E6-B6C8-301148214434Q39436696-6FFB5E6F-D44E-4651-9F6A-DA689688C353Q40332920-A0314BD8-3BEE-4448-98B6-E9623F4F94A7Q40539441-B7C26064-0EDA-4379-B5F9-9688315EC2E4Q40803726-D41A37D0-33A0-417A-BA62-948B6942B02BQ41353538-F20BE25D-F181-4691-AE33-DFD35C722DF7Q41958576-B1F7093E-CC0D-4A4B-A2BC-FC75C6952040Q42694340-4B65321A-19F3-44E9-8423-224D497804A5Q43669103-E1467F96-0F4D-478D-B2F5-66002C31EB07Q44032473-A5F40849-F640-41D5-AA05-2AB62888DBAFQ46155505-DF7FF033-1759-4ADD-A14A-758A27FEC88DQ48197038-9FCC2157-A720-40B6-B7A7-60245856ACCAQ49715547-C49E7C52-204F-48D7-B3D3-79D6A9639182Q51193196-8CE5933F-DC6C-4B13-8A7C-34D1F3583B9BQ51595733-61A84A68-A435-43A6-A614-F669E1E6F263Q52659389-79A0CA36-01DE-46D9-9784-1D53101F12E6Q53119430-6036E1A2-0F93-4903-8789-591B733E2C59Q54515075-6920D8E7-264B-46EC-A11A-E6DF70217B18Q55399322-DCB83C71-3D3E-496A-81D8-EE803B2F197DQ56035502-BB002275-CDB7-4ED3-99EB-6B5A59B6E74BQ57591319-ECCF948A-449F-4FC4-9653-4D80CAED3EFEQ57816680-CE46CDF3-8C92-486B-87EF-2429CA7851FC
P2860
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@ast
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@en
type
label
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@ast
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@en
prefLabel
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@ast
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@en
P1433
P1476
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
@en
P2093
C M Spencer
P2860
P304
P356
10.2165/00003495-200059030-00012
P577
2000-03-01T00:00:00Z
P6179
1044142052